Lachesis Snares ￥150M in Series B+ round

According to Yiou.com, Shenzhen Lachesis Mhealth ("Lachesis") has received 150 million yuan in a Series B+ round of financing, which is the first financing event in the Chinese medtech field in 2020, with participation from Shenzhen Capital Group and ShenZhen GTJA Investment Group. Proceed of this financing will be used for research and development of smart medical products and on new medical big data and smart diagnosis ventures. Previously, Lachesis closed its US$29 million Series B round, led by GTJA, in August 2018.

The success of this fresh fund is based on the product innovation ability and marketing ability in the medtech sector of Lachesis. Founded in 2010, Lachesis aims to provide "smart" wards and chronic disease management solutions for hospitals by sticking to clinical practice. From the initial single product and product portfolio to the smart ward interactive platform as the core of the overall solution, Lachesis has completed its strategic transformation.

Lachesis's business covers medical intelligent hardware, app, system platform, Internet of things and big data, forming the ecological chain for the construction of an intelligent hospital. Its marketing network covers more than 6000 hospitals and has accumulated more than 900 hospital users. Among them, 15 have been ranked among the top 20 hospitals in China, including top-tier hospitals such as Peking Union Medical College Hospital and Peking University People's Hospital.

Zhu Shuangquan, chairman of Lachesis, said, "the 'smart' ward is closest to the market demand. It is easier to expand the smart medical system from this aspect."

Shenzhen Capital Group is a limited venture capital company established by Shenzhen Government in 1999. The company has a registered capital of 5.42 billion RMB. It primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. 

Founded in Shenzhen in 2001, GIG is dedicated to investment in healthcare industry with a focus on strategic equity investment. GIG is involved in the entire investment stages which include M&A, PE, VC, and angel investment.

GIG has an AUM of ￥20 billion and has raised 24 funds dedicated to the healthcare industry.